This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. FDA, and one long-term safety study. The two pivotal programs will enroll approximately 500 patients per study at over 100 sites around the U.S. The primary endpoint of the pivotal studies is the cumulative incidence of gastric ulcers over the six-month treatment period for PA32540 versus 325 mg of enteric-coated aspirin. The long-term study will enroll approximately 400 patients and assess safety over a period of one year. Pozen is developing PA-325/40 for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers. Aspirin is the No. 1 recommended agent for at-risk ...

Neuromed and CombinatoRx, Incorporated (NASDAQ:CRXX)has agreed to sign a definitive merger agreement valued $28.8 million USD on 30th June, 2009 according to a news published by the RTT News.

Although the “merger” declaration with privately held Neuromeds Pharmaceutical Inc. did give a much required market boost, premarket trades for CombinatoRx Inc fell by 34 pct as reported by Reuters November 16th, 2009.

Regardless of the market fall for CombinatoRx, both companies are still sticking to the merger agreement and expected to close the transaction on 22nd November, 2009. Coincidentally, a pain killer drug “Exalgo” announced by Neuromed is in its current form not sufficient for approval under Section 505(b)(1) of the Food, Drug and Cosmetic Act of 1938, as amended (FDCA)

Exalgo, developed by ALZA Corp, is an “extended release” hydromorphone formulation, targeted for pain relief. U.S. marketing rights to this drug was sold

...

MivInvestments Inc. has initiated an independent bullish technical trading alert for 11/20/09 on Echo Therapeutics, Inc. (OTC:ECTE.OB). Shares of the company finished the day at $1.35, up 8.15% from the opening bell on heavy buying pressure. The excitement was due to the announcement on positive results of a clinical study testing symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes. Despite the fact that there has been a recent common shares financing scheduled, companies usually take their time and let the price consolidate before engaging in these activities, thus a short-term buy could be a smart investment. Towards the end of this alert a technical analysis will also be issued.

According to the ADA, the cost of diabetes care in the United States in 2007 was more than $174 billion, including $116 billion in excess medical expenditures attributed to diabetes and

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Friday November 20, 2009 are:

**************************************************************

KEI, Keithley Instruments Inc.

KEI designs, develops, manufactures, and markets electronic instruments and systems for use in production testing, process monitoring, product development, and research. KEI offers approximately 500 products to source, measure, connect, control, or communicate direct current, radio frequency (RF), or optical signals.

KEI has signed a definitive agreement with Agilent Technologies, Inc. to sell substantially all of its radio frequency “RF” product line to Agilent. KEI expects to receive cash proceeds of approximately $9 million and to realize a pre-tax gain in the range of $2.5 to $3.5

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Thursday November 18, 2009

DrStockPick.com Stock Report!

PWRM, HZHI, HCEI, CVAT, PSFT, TAXS, CSRH, AQNM

**************************************************************

HCEI, Healthy Coffee International Inc., HCEI.PK

HCEI is well positioned in the market place at the intersection of three mega-billion dollar industries: coffee, wellness and energy drinks, and has quickly established offices in 9 countries and distributors in 29 other countries through its marketing subsidiary Healthy Coffee USA, Inc. (www.HealthyCoffee.com) which uses a simple and unique Internet-driven international business model that allows the average person to own and operate a local, national, or international coffee distribution or coffee house

...

Skinvisible, Inc. is focused on developing innovative technology and superior topical polymer delivery vehicles to significantly enhance product performance for established brand manufacturers and marketers of Rx and OTC dermatological, medical, cosmetic and skincare products.

Skinvisible has developed a patented family of polymer delivery vehicles called Invisicare. The company uses the Invisicare technology to produce a variety of prescription dermatology and over-the-counter skincare products along with hospital-related and consumer goods products that address a variety of medical conditions.

The company conducts in-house research, development and testing of its Invisicare polymer delivery vehicles as well as the products formulated with Invisicare. In addition, where appropriate for validation and independent verification of marketing claims, it utilizes FDA registered independent laboratories for carrying out investigative product studies, utilizing protocols incorporating Good Lab Practice and Good Clinical Practice (”GLP/GCP”) standards.

Let us hear your thoughts: Skinvisible, Inc. Message Board

Pfizer (PFE) announced that the US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products advisory committee voted in favor (10 to 1) of data presented to support the safety and effectiveness of Prevnar 13, its 13-valent pneumococcal conjugate candidate vaccine. The favorable recommendation of the vaccine was based on data from 13 phase III studies carried out on more than 7,000 children.  Pfizer is seeking FDA approval for the vaccine to prevent diseases (including sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema caused by 13 Streptococcus pneumoniae (S. pneumoniae) in infants and young children. Although the FDA is not required to follow the advisory panel’s recommendation, it generally does so. The FDA is reviewing the Biologic License Application (BLA) for Prevnar 13, which has an action date of December 30, 2009. Though the FDA was initially expected to respond by September 30, 2009, the agency had ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Thursday Nov 19, 2009

DrStockPick.com Stock Report!

PWRM, PFE

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Thursday November 19, 2009 are:

**************************************************************

BRGO, Bergio International, Inc., BRGO.OB

BRGO is entering into its 20th year of operations and concentrates on boutique, upscale jewelry stores. BRGO currently sells its jewelry to approximately 150 independent jewelry retailers across the United States.

BRGO has spent millions in branding the Bergio brand through tradeshows, trade advertising, national advertising and billboard advertising since launching the line in 1995.

To consider about BRGO:

1.- BRGO has come to an agreement to launch the Bergio Collection in the Neiman Marcus stores, starting with

...

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the opening bell on heavy buying pressure. The spark which ignited the rise in share price is being speculated as being attributed due to the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 19-21, 2009, of which Power3 Medical will be attending. Excitement over the company is building, as they will now be exposed to over 50,000 scientists worldwide. Volume at the end of day was 21.62M as compared to the daily average of 2.6M.

About Power3 Medical Products, Inc.

…